Castration-resistant prostate cancer: AUA guideline amendment.
about
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerHealth Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the LiteratureAndrogen receptor splice variants and prostate cancer: From bench to bedside.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityDarolutamide (ODM-201) for the treatment of prostate cancerToremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trialBiomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Metabolism and pharmacokinetics of radium-223 in prostate cancer.Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to AntiandrogensIndirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.Understanding the role of new systemic agents in the treatment of prostate cancer.Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesRadium-223 and concomitant therapies: prospects and prudence.Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?Development of a stress response therapy targeting aggressive prostate cancer.Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.Recent trends in the management of advanced prostate cancerMarkers of Prostate Cancer: The Role of Circulating Tumor Markers in the Management of Bone Metastases
P2860
Q26739738-38E50EF1-2913-4A7D-AA63-04F89838F54FQ26747782-A3BA8187-0B2F-4321-B8FB-8625E8894594Q27004566-BE5787EA-15B0-455B-81E0-A785745D737EQ33567024-34FD7D92-07FD-4EEA-A315-B37E96F25F0EQ33656820-A540FB4B-8DDB-4F88-A357-2398A3875A09Q34556466-6EAAB424-5981-4EFB-89BE-4A18774FBD04Q35829785-1CCAD8C9-22EE-47F5-95FA-5076D6430410Q36407003-E5144CB1-18BD-474F-9F9A-6AD4ACFF2A33Q38367715-2FD2BD55-678F-40C6-A7CE-F18C722D890CQ38711529-3025C6A9-9D7E-48C2-8394-EC1355752B16Q38841385-7EABE63E-A8BA-4E82-88F5-92B7B09362D4Q38973445-2A7B6DA0-A3C4-4C45-9A59-A3A34FAC4F58Q40112141-3CB2194F-1BF4-4116-91D9-16F760689826Q41017874-FA36A731-1BEE-48A0-A382-ACC96B91C0A5Q41841139-058E05D7-DFE2-40ED-A802-625BAC4D54B9Q42343422-55919771-1DE0-41C1-9123-78B0F1351E4FQ48858773-DCBA5C9D-2EFD-4261-AD56-51EAAD6AB610Q52647565-14376E3A-EFDA-472B-BFEA-C720292719E8Q52714528-7E41B1E4-09F9-417E-A8AF-5840BD8CCAB2Q55020070-F39A5092-7F4B-4516-9CCE-58314A0830B3Q55158890-8E163524-D451-4767-8DF8-218019EC9ED9Q57821875-D6DDF64E-4CF0-455F-9661-6A83D0BFBDDAQ58487854-6791AB90-B559-4593-92E0-4FA265084908
P2860
Castration-resistant prostate cancer: AUA guideline amendment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Castration-resistant prostate cancer: AUA guideline amendment.
@en
type
label
Castration-resistant prostate cancer: AUA guideline amendment.
@en
prefLabel
Castration-resistant prostate cancer: AUA guideline amendment.
@en
P2093
P1476
Castration-resistant prostate cancer: AUA guideline amendment.
@en
P2093
Adam S Kibel
American Urological Association
Michael S Cookson
Mohammad H Murad
William T Lowrance
P304
P356
10.1016/J.JURO.2014.10.104
P407
P577
2014-10-31T00:00:00Z